A phase 2, open-label, multi-center study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients

Trial Profile

A phase 2, open-label, multi-center study to assess efficacy, safety and pharmacokinetics of a tacrolimus new oral formulation (MR4) in de novo bone marrow transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2006

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Graft-versus-host disease
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 27 Sep 2006 Status change
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top